Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Titel:
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Auteur:
Dimopoulos, Meletios A Moreau, Philippe Palumbo, Antonio Joshua, Douglas Pour, Ludek Hájek, Roman Facon, Thierry Ludwig, Heinz Oriol, Albert Goldschmidt, Hartmut Rosiñol, Laura Straub, Jan Suvorov, Aleksandr Araujo, Carla Rimashevskaya, Elena Pika, Tomas Gaidano, Gianluca Weisel, Katja Goranova-Marinova, Vesselina Schwarer, Anthony Minuk, Leonard Masszi, Tamás Karamanesht, Ievgenii Offidani, Massimo Hungria, Vania Spencer, Andrew Orlowski, Robert Z Gillenwater, Heidi H Mohamed, Nehal Feng, Shibao Chng, Wee-Joo